🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsDosing & ProtocolsMicro-dosing semaglutide — 12 month update Page 2

Micro-dosing semaglutide — 12 month update

FDA_TrackerJim Fri, Apr 17, 2026 at 10:57 AM 17 replies 874 viewsPage 2 of 4
RetaRick_CA
VIP Member
2,012
9,876
Jan 2024
California
Apr 17, 2026 at 12:11 PM#6
TrialNerd_Beth said:
The mechanism that matters here is not stomach emptying, it is central.

I read this differently from TrialNerd_Beth, on substance rather than tone. Halving the dose and calling it splitting is not the same intervention, and this thread keeps mixing them. One changes the schedule; the other changes the exposure.

I would rather be corrected than agreed with, if it comes to it.

30 0SkepticalSean, Dr.CardioMD, EndoResFellow and 27 others
Reply Quote Save Share Report
PeptideSynthNJ
Member
234
1,234
Aug 2024
Princeton, NJ
Apr 17, 2026 at 12:39 PM#7

The figures, for anyone assembling their own picture. For anyone assembling their own picture: Tmax is one to three days, terminal half-life about 165 to 170 hours, steady state at four to five weeks, and subcutaneous bioavailability near 89%. Those four numbers explain most of the questions people ask about timing.

29 24NurseAsh_DET, BenResearch_OR, MikeKY_noInsulin and 26 others
Reply Quote Save Share Report
LindaRN_retired
Member
189
890
Dec 2024
Sarasota, FL
Apr 17, 2026 at 1:07 PM#8
RetaRick_CA said:
Halving the dose and calling it splitting is not the same intervention, and this thread keeps mixing them.

There is a second half to this that has not been said yet. The dose-response is real but shallow at the top. Across STEP 1 and STEP 4 the gap between 1.7mg and 2.4mg is a couple of percentage points of body weight on average, and the average is carrying a wide spread — plenty of people at 1.7mg sit above the 2.4mg mean. If a dose is working and tolerable, "working" is the relevant variable, not "maximal".

28 23amsterdam_pete, LondonLisa, mike_nyc and 25 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
BiostatsBrad
Member
456
2,345
Jul 2024
Durham, NC
Apr 17, 2026 at 1:35 PM#9

One thing that is still open after amsterdam_pete’s answer:

How much of the between-person variation is pharmacokinetic and how much is just adherence measured badly?

27 22james_edin, FranDenver, Dr.BariatricHTX and 24 others
Reply Quote Save Share Report
FDA_TrackerJim
Senior Member
1,567
7,890
Feb 2024
Rockville, MD
Apr 17, 2026 at 3:51 PM#10

Reporting back.

Following this thread I went back and re-read the extension data properly. The point about trough rather than peak explains the pattern I was seeing on day six, which I had been blaming on the vial.

Last edited: Apr 17, 2026 at 6:51 PM
13 11jason_paloalto, Dr.LeslieOBGYN, MikeNYC_runner and 10 others
Reply Quote Save Share Report

Similar Threads

Micro-dosing semaglutide — is sub-therapeutic dosing effective?16 replies
Injection technique: subcutaneous depot formation and absorption8 replies
Semaglutide PK modeling — when to time your injection12 replies
Reconstitution calculator — compounded peptide dosing math7 replies
Half-life implications for missed doses — PK-based guidance5 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register